Sonnet BioTherapeutics Holdings, Inc.·4

Aug 21, 4:48 PM ET

Kenney Richard T 4

4 · Sonnet BioTherapeutics Holdings, Inc. · Filed Aug 21, 2025

Insider Transaction Report

Form 4
Period: 2025-06-30
Kenney Richard T
Chief Medical Officer
Transactions
  • Award

    Warrant

    2025-06-30+86,50586,505 total
    Exercise: $1.16From: 2025-06-30Exp: 2030-06-30Common Stock (86,505 underlying)
  • Award

    Series 5 Preferred Stock

    2025-07-14+200200 total
    Exercise: $1.25From: 2025-07-14Common Stock (160,000 underlying)
  • Award

    Warrant

    2025-07-14+320,000320,000 total
    Exercise: $1.25From: 2025-07-14Exp: 2030-07-14Common Stock (320,000 underlying)
Footnotes (3)
  • [F1]On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of common stock, par value $0.0001 ("Common Stock") as partial consideration for a convertible note (the "Convertible Note") issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
  • [F2]On July 14, 2025, the Reporting Person was issued warrants to purchase up to 320,000 shares of Common Stock upon the conversion in full of the Convertible Note. The warrants cannot be exercised to the extent that, after giving effect to such exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock.
  • [F3]On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4